NCT07516132Phase 3Recruiting

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Study sponsor: Ocular Therapeutix, Inc. · OCUL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-08-01Estimated
Enrollment · participants850Estimated
Source updated2026-07-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source